Clinical Trial Commences for Drug Eluting Stent

Published date : 14 January 2013
Article date : 14 January 2013

 

Massdevice reports that medical device manufacturer Abbott has initiated the Absorb III clinical trial which will evaluate its drug-eluting bioresorbable stent in patients with coronary artery disease. According to a press release from the company, the stent is made of polylactide, a naturally dissolvable material.
 
The article says that 2,250 patient trial will compare target lesion failure rates between Absorb and Abbott's market-leading Xience drug-eluting stent which received FDA clearance this month and CE Mark approval in August last year. 
 
Abbot also intends to evaluate vasomotion of some patients, measuring whether natural motion returns to the vessel after using the Absorb device.  
 
Source: Massdevice, 10 January 2013
 
Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.